Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Koenig – page 2

1 643 clinical trials in Bad Koenig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Koenig at a glance
1 643
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 643 trials in Bad Koenig

Open in trial search

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:PF-07275315
  • Sponsor:Pfizer Inc.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Neurodermatitis

Recruiting

ICP-332 for Adults with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Soficitinib
  • Sponsor:Innocare Pharma Inc.

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Koenig

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. These studies are investigating innovative approaches for patients undergoing regular dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

Current research aims to evaluate new therapeutic interventions targeting C-reactive protein levels, a key marker of inflammation in cardiovascular disease, potentially offering new hope for dialysis patients dealing with cardiovascular complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.